Medscape10h
Trastuzumab Emtansine Ups Long-term Survival in HER2-Positive Breast Cancer
Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...
Phase III trial finds trastuzumab emtansine improves long-term survival in HER2 breast cancer
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...
Hosted on MSN1h
Survival Benefit With Adjuvant T-DM1 in High-Risk HER2-Positive Breast Cancer
Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...
Healio13h
Adjuvant regimen extends survival in early HER2-positive breast cancer
Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...
Govt may propose duty cuts for rare-disease medicines, cancer drugs in budget to ease burden on patients
The landscape of rare diseases is constantly changing as new ailments and conditions are identified and reported regularly.
The 6 signs of ‘hard to spot’ bile duct cancer that kills majority of patients within a year
FOR the 6,000 people in the UK who are newly diagnosed with bile duct cancer every year, the prognosis is uniquely grim.
The American Journal of Managed Care4h
Innovations in Breast Cancer Treatment With Dr Dawn Klemow
Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.
New hope for patients with deadly bile duct cancer
In the new study, patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal ...
GlobalData on MSN2d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...